CareStart COVID-19 Molecular
COVID-19
Key Facts
About Access Bio
Access Bio is a commercial-stage diagnostics company with a 20+ year history focused on combating infectious diseases in global health settings. It successfully leveraged its IVD platform to become a significant player in the COVID-19 response, securing multiple FDA Emergency Use Authorizations (EUAs) for antigen, antibody, and molecular tests under its CareStart™ brand. While COVID-19 products were a major recent focus, the company's core expertise and legacy are in malaria and other serious tropical diseases, supplying tests to organizations in low-resource regions. The company appears to have a public listing via Korean Depository Receipts (KDRs), indicating a complex corporate structure with operations in the US and South Korea.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |